AN2 THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.275 USD | -1.52% |
|
-7.17% | -88.95% |
| Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
| Apr. 02 | JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform | MT |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 184.9 | 609.4 | 68.91 | - | - |
| Enterprise Value (EV) 1 | 85.63 | 609.4 | 17.11 | -13.39 | -29.89 |
| P/E ratio | -3.42 x | -7.48 x | -0.9 x | -0.98 x | -2.86 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 1.86 x |
| EV / Revenue | - | - | - | - | -0.81 x |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 19,403 | 29,741 | 29,829 | - | - |
| Reference price 2 | 9.530 | 20.49 | 2.310 | 2.310 | 2.310 |
| Announcement Date | 3/29/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 37.03 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | - | -42.26 | -69.64 | -79.05 | -87.45 | -17.8 |
| Operating Margin | - | - | - | - | - | -48.06% |
| Earnings before Tax (EBT) | - | - | -64.73 | - | - | - |
| Net income 1 | -28.06 | -42.78 | -64.73 | -70.6 | -96.8 | -72.55 |
| Net margin | - | - | - | - | - | -195.9% |
| EPS 2 | -25.02 | -2.790 | -2.740 | -2.565 | -2.355 | -0.8067 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/4/22 | 3/29/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -7.683 | -10.33 | -11.77 | -12.48 | -16.04 | -16.6 | -18.18 | -18.82 | -18.3 | -19.6 | -19.8 | -20.3 | -20 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | -16.9 | - | - | - | - | - |
| Net income 1 | -9.475 | -10.12 | -11.34 | -11.84 | -15.32 | -15.8 | -16.71 | -16.9 | -16.62 | -17.8 | -17.8 | -18.3 | -20 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -2.980 | -0.5300 | -0.5900 | -0.6100 | -0.7900 | -0.8100 | -0.6500 | -0.5700 | -0.5600 | -0.6300 | -0.6525 | -0.6650 | -0.6700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 5/10/22 | 8/11/22 | 11/9/22 | 3/29/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/28/24 | 5/14/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 99.3 | - | 51.8 | 82.3 | 98.8 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 3/4/22 | 3/29/23 | 3/28/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
2.31
USD
Average target price
6
USD
Spread / Average Target
+159.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -88.73% | 68.91M | |
| +29.03% | 49.18B | |
| -0.10% | 42.11B | |
| +43.45% | 40.37B | |
| -5.26% | 28.85B | |
| +11.48% | 26.09B | |
| -22.74% | 18.71B | |
| +9.06% | 13.26B | |
| +30.01% | 12.32B | |
| -1.51% | 11.99B |
- Stock Market
- Equities
- ANTX Stock
- Financials AN2 Therapeutics, Inc.